Yifan Pharmaceutical Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Yifan Pharmaceutical Co Ltd with three other
companies in this sector in China:
China Biologic Products Holdings Inc
sales of 2.27 billion Chinese Renmimbi [US$358.53 million]
of which 100%
was Human Blood Product),
Shanghai Raas Blood Products Company Limited
(2.33 billion Chinese Renmimbi [US$367.43 million]
of which 97%
was Blood products production and sales), and
China Animal Husbandry Ind.
(3.97 billion Chinese Renmimbi [US$627.67 million]
of which 48%
was Animal Feedstuff).
Yifan Pharmaceutical Co Ltd reported sales of 3.50 billion Chinese Renmimbi (US$553.45 million)
December of 2016.
increase of 43.9%
versus 2015, when the company's sales were 2.43 billion Chinese Renmimbi.
Sales at Yifan Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 607%).
Sales of Medicine Material and Macromolecular saw an increase
that was more than double the company's growth rate: sales were up
106.5% in 2016, from
777.74 million Chinese Renmimbi to 1.61 billion Chinese Renmimbi.